Back to Search
Start Over
Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade glioma.
- Source :
-
Neuro-oncology advances [Neurooncol Adv] 2024 Aug 06; Vol. 6 (1), pp. vdae131. Date of Electronic Publication: 2024 Aug 06 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Radiotherapy (RT) plays an integral role in the management of low-grade gliomas (LGG). Late toxicity from RT can cause progressive neurocognitive dysfunction. Radiation-induced damage to the hippocampus (HCP) plays a considerable role in memory decline. Advancements in photon planning software have resulted in the development of multi-criteria optimization (MCO) and HyperArc technologies which may improve HCP sparing while maintaining planning target volume (PTV) target coverage.<br />Methods: Three planning methods for hippocampal sparing (HS) were compared, volumetric modulated arc therapy (VMAT) without HS (VMAT&#95;noHS), VMAT with HS (VMAT&#95;HS), MCO with HS (MCO&#95;HS), and HyperArc with HS (HyperArc&#95;HS).<br />Results: Twenty-five patients were identified. The contralateral HCP was spared in 16 patients and bilateral HCP in 9 patients with superiorly located tumors. All 3 HS planning techniques showed significant reductions in dose to the spared HCP in contralateral cases but only VMAT&#95;HS and MCO&#95;HS achieved this in bilateral cases ( P < .008). Only MCO&#95;HS was superior to VMAT&#95;HS in lowering the dose to both contralateral HCP and bilateral HCP in all measured metrics ( P < .008). PTV and OAR (organ at risk) dose constraints were achieved for all plans.<br />Conclusions: This retrospective dosimetric study demonstrated the feasibility of HS for low-grade glioma. All 3 HS planning techniques achieved significant dose reductions to the spared contralateral hippocampus, but only MCO&#95;HS and VMAT&#95;HS achieved this in bilateral cases. MCO was superior to other planning techniques for sparing both bilateral and contralateral hippocampi.<br />Competing Interests: The authors have no relevant disclosures.<br /> (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
Details
- Language :
- English
- ISSN :
- 2632-2498
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Neuro-oncology advances
- Publication Type :
- Academic Journal
- Accession number :
- 39220244
- Full Text :
- https://doi.org/10.1093/noajnl/vdae131